A股異動 | 翰宇藥業午後拉漲逾7% 鹽酸曲美他嗪緩釋片擬中選全國藥品集採
格隆匯1月20日丨翰宇藥業(300199.SZ)午後拉昇,現報5.84元,漲7.16%,暫成交7696萬元,最新總市值53.5億元。翰宇藥業午間發公告稱,公司藥品鹽酸曲美他嗪緩釋片擬中選聯合採購辦公室組織的第二批國家組織藥品集中採購項目。擬中選價格為14.04元,擬中選數量為1984.07萬片。公司表示,本次擬中選產品鹽酸曲美他嗪緩釋片在2019年6月獲得國家藥監局核准簽發的《藥品註冊批件》,根據化學藥品新註冊分類標準,視同通過仿製藥一致性評價,截至目前暫未實現銷售。在國家組織集採項目確定中選並實施後,產品有望迅速打入市場,提高市場佔有率,促進相關產品國內市場的開拓,提升公司品牌影響力,對公司未來經營產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.